Abstract：Objective To study the correlations between levels of serum amyloid A protein (SAA), retinol binding protein (RBP4), monocyte chemotactic protein (MCP-1) and the NIHSS score of ischemic stroke patients.Methods Fifty cases of elderly inpatients diagnosed with acute ischemic stroke between January 2013 and January 2015 were selected as the observation group, while another 50 healthy people served as the control group. The serum levels of SAA, RBP4 and MCP-1 were compared between the two groups. According to the NIHSS scores of these patients, the observation group was divided into the mild, moderate and severe groups of neural impairment. Serum levels of MCP-1, SAA and RBP4 were compared between the three groups, so were prognosis, rates of progressive stroke and mortality.Results According to the study, serum MCP-1, SAA and RBP4 levels were higher in the observation group than in the control group, and the difference was statistically significant (P<0.05).Serum MCP-1, SAA and RBP4 levels were gradually increased in the observation group compared with the mild, moderate and severe groups, and the difference was also statistically significant (P<0.05). Serum MCP-9, SAA and RBP4 levels in the observation group were decreased considerably three, five and seven days after hospitalization compared with one day after hospitalization, and the difference was of statistical significance. There were twelve mild cases, eighteen moderate cases and twenty severe cases according to the NIHSS scores. Conclusions Serum, MCP-1, SAA and RBP4 levels of acute ischemic stroke patients are significantly increased and are positively correlated with the severity of the disease, so they can be used as laboratory indicators for the diagnosis of the disease.
2019, Vol. 30 
